This trial is evaluating whether Gemcitabine will improve 1 primary outcome and 3 secondary outcomes in patients with Breast Cancer. Measurement will happen over the course of Cycle 1 Day 1 (each cycle is 21 days) up to 14 months.
This trial requires 250 total participants across 2 different treatment groups
This trial involves 2 different treatments. Gemcitabine is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
Breast cancer treatment is highly dependent on a number of factors, primarily related to the [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) type. There are currently no effective treatments for the majority of cancer types or with the exception of mastectomy type 2 (a mastectomy with breast tissue removal, but with the breast reconstructed by implantation of silicone gel or silicone-filled breast implants), where mastectomy type 1 (a mastectomy with breast tissue removal, with or without reconstructive surgery after mastectomy), is the standard of care. It is important to learn the basics of treatments for breast cancer. Treatment must follow accepted national and international guidelines, as well as individual patient needs.
Nearly one in 25 women will be diagnosed with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in her lifetime. Breast cancer is the most frequent cancer and the most common cause of death from cancer among women in this report.
The evidence that breast and ovarian cancer are closely associated suggests that endocrine disrupting agents may play a role in tumorigenesis and the role of diet and environmental factors in the development of breast cancer. It has also been clearly shown that genetic factors play a role in the risk of developing breast cancer.
The signs and symptoms of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) can result from secondary causes. All patients with new or unexplained symptoms of a malignant lump, and every patient with a past history of breast disease should be screened for cervical or breast cancer.\n
A patient with Breast cancer usually has an unexplained lump in the breast or nipple or she has a change in the shape, size or colour of the breast. There can be a range of signs and symptoms associated with breast cancer. Breast cancer is often diagnosed during the screening programmes of breast cancer. In 2015, Breast cancer was the cause of 1 in 9 deaths in GB, and in the year after (2011–2) this accounted for 1 in 36.5 of cancer deaths.\n
There are limited data available in the English-language literature to support the idea that most [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer)s can be cured. More research is warranted. Patients' desires for a cure for their disease are widely discussed in the literature, however, because patients who identify as having cancer may be more concerned about the possibility of cure than about dying, these discussions should be reported with caution.
Gemcitabine, in contrast to its clinical use to treat cancers, does not appear to exert the desired effect on normal cells. There is a strong desire for clinical trials to evaluate the activity of gemcitabine in the treatment of cancers, even on normal tissues, as has been done for other chemotherapeutic agents used in cancer therapy
We could not identify any patient who actually received gemcitabine for [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). This may be because the authors' search for treatments in the article's title was insufficient. Thus, patients do not need to have breast cancer to receive gemcitabine, but patients with this cancer type often are eligible for gemcitabine as part of the treatment. Therefore, it is difficult to tell why the authors chose this particular drug as its own treatment in the first place.
On the basis of the findings in this study, it appears as though gemcitabine does not appear to be effective in patients who have previously received neoadjuvant/adjuvant chemotherapy. Results from a recent paper are discussed in terms of possible molecular mechanisms of cytotoxicity, the role of gemcitabine metabolism or uptake, or the possibility of alternative mechanisms of cell death in chemotherapy-treated breast cancer.
Survival for early breast cancer has substantially improved over the past 50 years with the current 5-year survival rate for stage II breast cancer estimated to be 91%. I am not very well but my recurrence did not show in the bone or brain either.
Gemcitabine combined with some chemotherapy regimens is one of the most commonly used medicines within the NHS. However, when the combination contains only gemcitabine, the cost of treatment increases. Although the cost of gemcitabine treatment of breast cancer using an intravenous infusion is still about £12,000 per cycle, the cost of administration with paclitaxel and docetaxel has risen by nearly £30,000 since the introduction of gemcitabine and pemetrexed-based regimens. The NHS budget must, therefore, be mindful of the need to restrict the number and type of combinations of chemotherapy drugs available, in order to reduce the overall cost of treatment.
The study is one of the first investigations into the use of gemcitabine to treat breast cancer. The research findings show positive results and potential role for this compound on the treatment of breast cancer as an effective cytotoxin or chemotherapeutic agent. Although the underlying mechanism of action for gemcitabine is yet to be fully elucidated, further study into their use for the treatment of breast cancer is warranted.